武汉大学人民医院湖北省人民医院

院内导航

刘修恒 泌尿外科学
武汉大学人民医院泌尿外科首席专家，武汉大学人民医院教授委员会主任委员，二级教授、一级主任医师，博士生导师，留日、留美学者，湖北省首届医学领军人才。

A+ A-

导师介绍

姓名	刘修恒
出生年月	1962年7月
单位	武汉大学人民医院泌尿外科
所属学科	临床医学-外科学
职务、职称及头衔	武汉大学人民医院泌尿外科首席专家，武汉大学人民医院教授委员会主任委员，二级教授、一级主任医师，博士生导师，留日、留美学者，湖北省首届医学领军人才。
E-mail	drliuxh@hotmail.com
联系方式	027-88041911转81101或13339999350
研究方向	1.前列腺癌免疫及基因治疗研究 2.肾移植免疫耐受
个人简介	主要从事前列腺癌免疫及基因治疗研究、肾移植免疫耐受等研究。擅长泌尿外科各种疑难疾病诊疗及微创手术治疗。武汉大学跨世纪学科带头人，湖北省首届医学领军人才。曾在日本滋贺医科大学、美国迈阿密大学访问学习。主持国家自然科学基金面上项目、湖北省科技厅重点攻关计划、湖北省卫健委重点支撑项目、武汉市科技局重点项目等20余项，获得湖北省科技进步奖4项，主编参编专著11余部，发表论著200余篇，SCI100余篇；已培养博士生60余名，硕士生100余名。
学术任职与荣誉	中国医师协会泌尿外科医师分会委员亚洲男科学会常务委员中国医师协会男科医师分会指导委员会副主任委员卫生部内镜专业技术考评委员会常务理事中华医学会泌尿外科分会机器人学组委员中国研究型医院学会泌尿外科分会常务委员海峡两岸泌尿外科分会常务委员湖北省临床肿瘤学会泌尿生殖肿瘤专委会主任委员《中华器官移植杂志》编委《临床外科杂志》常务编委《临床泌尿外科杂志》编委《中华内分泌杂志》编委《中华泌尿外科杂志电子版》编委《泌尿精选合集》编委《器官移植杂志》编委《微循环杂志》编委
教育履历	1979.09-1984.08湖北医学院临床医学专业本科生获学士学位 1984.09-1987.07湖北医学院外科学硕士研究生获硕士学位 1991.09-1992.09日本滋贺医科大学泌尿器科研修 2000.09-2003.12武汉大学外科学博士研究生获博士学位 2003.03-2003.04美国迈阿密大学访问学者
工作履历	1987.07-1992.08湖北省人民医院泌尿外科住院医师 1992.08-1997.10湖北省人民医院泌尿外科主治医师 1997.10-2002.12武汉大学人民医院泌尿外科副主任医师、副教授 2002.12-2003.12武汉大学人民医院泌尿外科主任医师、副教授 2003.12-至今武汉大学人民医院泌尿外科主任医师、教授
成果获奖	1.《输精管过滤装置可复性节育术的实验研究》1991年获湖北省科技进步三等奖 2.《前列腺癌组织中HNK-1抗原的分布及其对预后判断的意义》2001年获湖北省科技进步三等奖 3.《镰刀状肾实质切开术治疗复杂性结石》2004年湖北省科技进步二等奖 4.《前列腺精准医疗的相关机制及临床应用》2019年获湖北省科技进步二等奖
代表性论著	1. Li J, Liu X.Coptisine inhibits the malignancy of bladder carcinoma cells and regulates XPO1 expression. Chem Biol Drug Des. 2023 Jul 13. (通讯作者) 2.Xia K, Qiu T, Jian Y, Liu H, Chen H,Liu X, Chen Z, Wang L.Degradation of histone deacetylase 6 alleviates ROS-mediated apoptosis in renal ischemia-reperfusion injury.Biomed Pharmacother. 2023 Jul 8;165:115128. (通讯作者) 3.Xu K, Zhang Y, Yan Z, Wang Y, Li Y, Qiu Q, Du Y, Chen Z, Liu X.Identification of disulfidptosis related subtypes, characterization of tumor microenvironment infiltration, and development of DRG prognostic prediction model in RCC, in which MSH3 is a key gene during disulfidptosis.Front Immunol. 2023 Jun 23;14:1205250.(通讯作者) 4.Zheng Q, Yang R, Xu H, Fan J, Jiao P, Ni X, Yuan J, Wang L, Chen Z, Liu X. A Weakly Supervised Deep Learning Model and Human-Machine Fusion for Accurate Grading of Renal Cell Carcinoma from Histopathology Slides. Cancers (Basel). 2023 Jun 5;15(12):3198. (通讯作者) 5.Hou Y, Liu J, Huang S, Wang L, Hu J, Liu X. DOT1L Epigenetically Regulates Autophagy and Mitochondria Fusion in Cell Lines of Renal Cancer. Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338231167249. (通讯作者) 6.Zheng Q, Jian J, Wang J, Wang K, Fan J, Xu H, Ni X, Yang S, Yuan J, Wu J, Jiao P, Yang R, Chen Z, Liu X, Wang L.Predicting Lymph Node Metastasis Status from Primary Muscle-Invasive Bladder Cancer Histology Slides Using Deep Learning: A Retrospective Multicenter Study. Cancers (Basel). 2023 May 31;15(11):3000. (通讯作者) 7. Xiong Y, Jian J, Yu H, Wu J, Mao H, Feng R, Wang L, Jian Y, Liu X. Cyanidin-3-O-glucoside plays a protective role against renal ischemia/ reperfusion injury via the JAK/STAT pathway. Acta Cir Bras. 2023 May 1;38:e381023. (通讯作者) 8. Liu Y, Jian J, Zhang Y, Wang L, Liu X, Chen Z. Construction of cancer- associated fibroblasts related risk signature based on single-cell RNA-seq and bulk RNA-seq data in bladder urothelial carcinoma. Front Oncol. 2023 Apr 14;13:1170893. (通讯作者) 9. Zheng Q, Guo L, Yang R, Chen Z, Liu X. Identification of essential genes and drug discovery in bladder cancer and inflammatory bowel disease via text mining and bioinformatics analysis. Curr Comput Aided Drug Des. 2023 Mar 30. (通讯作者) 10.Zheng Q, Yang R, Yang S, Ni X, Li Y, Jiang Z, Wang X, Wang L, Chen Z, Liu X.Development and validation of a deep-learning based assistance system for enhancing laparoscopic control level.Int J Med Robot. 2022 Aug 3:e2449. doi: 10.1002/rcs.2449 (通讯作者) 11.Feng R, Xiong Y, Lei Y, Huang Q, Liu H, Zhao X, Chen Z, Chen H,Liu X, Wang L, Weng X.Lysine-specific demethylase 1 aggravated oxidative stress and ferroptosis induced by renal ischemia and reperfusion injury through activation of TLR4/NOX4 pathway in mice. J Cell Mol Med. 2022 Aug;26(15):4254-4267 (通讯作者) 12.Xiong Y, Pang M, Du Y, Yu X, Yuan J, Liu W, Wang L, Liu X. The LINC01929/miR-6875-5p/ADAMTS12 Axis in the ceRNA Network Regulates the Development of dvanced Bladder Cancer. Front Oncol. 2022 May 12;12:856560 (通讯作者) 13.Mao H, Wang L, Xiong Y, Jiang G, Liu X. Fucoxanthin Attenuates Oxidative Damage by Activating the Sirt1/Nrf2/HO-1 Signaling Pathway to Protect the Kidney from Ischemia-Reperfusion Injury. Oxid Med Cell Longev. 2022 Jan 28;2022:7444430 (通讯作者) 14.Wang T, Chen Z, Chen H, Yu X, Wang L, Liu X. Brusatol inhibits the growth of renal cell carcinoma by regulating the PTEN/PI3K/AKT pathway.J Ethnopharmacol. 2022 Apr 24;288:115020 (通讯作者) 15.Zhang BH, Liu H, Yuan Y, Weng XD, Du Y, Chen H, Chen ZY, Wang L, Liu XH. Knockdown of TRIM8 Protects HK-2 Cells Against Hypoxia/Reoxygenation-Induced Injury by Inhibiting Oxidative Stress-Mediated Apoptosis and Pyroptosis via PI3K/Akt Signal Pathway. Drug Des Devel Ther. 2021 Dec 10;15:4973-4983 (通讯作者) 16.Zhang J, Chen H, Weng X, Liu H, Chen Z, Huang Q, Wang L, Liu X. RCAN1.4 attenuates renal fibrosis through inhibiting calcineurin-mediated nuclear translocation of NFAT2.Cell Death Discov. 2021 Oct 27;7(1):317 (通讯作者) 17.Zhao X, Wang D, Wan S, Liu X, Wang W, Wang L. The Suppression of Pin1-Alleviated Oxidative Stress through the p38 MAPK Pathway in Ischemia- and Reperfusion-Induced Acute Kidney Injury. Oxid Med Cell Longev. 2021 Jul 30;2021:1313847(通讯作者) 18.Wang X, Guo J, Wang L, Wang M, Weng X, Chen H, Liu X. Modified completely intrafascial radical cysprostatectomy for bladder cancer: a single-center, blinded, controlled study.BMC Cancer. 2021 Aug 3;21(1):887(通讯作者) 19.Liu H, Wang W, Weng X, Chen H, Chen Z, Du Y, Liu X, Wang L. The H3K9 histone methyltransferase G9a modulates renal ischemia reperfusion injury by targeting Sirt1. Free Radic Biol Med. 2021 Aug 20;172:123-135(通讯作者) 20.Qin XK, Du Y, Liu XH, Wang L. LSD1 Promotes Prostate Cancer Cell Survival by Destabilizing FBXW7 at Post-Translational Level. Front Oncol. 2021 Feb 23;10:616185(通讯作者)

Name	Xiuheng Liu
Date of birth	July,1962
Department	Department of Urology, Renmin Hospital of Wuhan University
Title	Medical Doctor, Professor, Director, Doctoral tutor, The scholar studied in Japan and America, The visiting scholar of European and American countries, First Medical Leader in Hubei Province.
Email	drliuxh@hotmail.com
TEL	027-88041911转81101或13339999350
Research Direction	1. Immunotherapy and gene therapy for prostate cancer 2. Immune tolerance in renal transplantation
Personal Profile	Professor Liu is mainly engaged in researches on immunotherapy and gene therapy for prostate cancer, and on immune tolerance in renal transplantation. He has a great reputation for diagnosis of intractable cases and varieties of minimally invasive surgeries of Urology. He was selected as the trans-century academic leader of Wuhan University and the subject bellwether in Urology of Hubei Province. He has been awarded over 20 items from National Natural Science Foundation, the Provincial Science and Technology Department, the Provincial Education Commission and the Provincial Health Department. He has also involved in compiling more than 11 monographs. Besides, there are more than 200 articles published including nearly 60 SCI papers. By now, he has educated 60 PhD students and 100 master students.
Selected Publications	1. Li J, Liu X.Coptisine inhibits the malignancy of bladder carcinoma cells and regulates XPO1 expression. Chem Biol Drug Des. 2023 Jul 13. (通讯作者) 2.Xia K, Qiu T, Jian Y, Liu H, Chen H,Liu X, Chen Z, Wang L.Degradation of histone deacetylase 6 alleviates ROS-mediated apoptosis in renal ischemia-reperfusion injury.Biomed Pharmacother. 2023 Jul 8;165:115128. (通讯作者) 3.Xu K, Zhang Y, Yan Z, Wang Y, Li Y, Qiu Q, Du Y, Chen Z, Liu X.Identification of disulfidptosis related subtypes, characterization of tumor microenvironment infiltration, and development of DRG prognostic prediction model in RCC, in which MSH3 is a key gene during disulfidptosis.Front Immunol. 2023 Jun 23;14:1205250.(通讯作者) 4.Zheng Q, Yang R, Xu H, Fan J, Jiao P, Ni X, Yuan J, Wang L, Chen Z, Liu X. A Weakly Supervised Deep Learning Model and Human-Machine Fusion for Accurate Grading of Renal Cell Carcinoma from Histopathology Slides. Cancers (Basel). 2023 Jun 5;15(12):3198. (通讯作者) 5.Hou Y, Liu J, Huang S, Wang L, Hu J, Liu X. DOT1L Epigenetically Regulates Autophagy and Mitochondria Fusion in Cell Lines of Renal Cancer. Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338231167249. (通讯作者) 6.Zheng Q, Jian J, Wang J, Wang K, Fan J, Xu H, Ni X, Yang S, Yuan J, Wu J, Jiao P, Yang R, Chen Z, Liu X, Wang L.Predicting Lymph Node Metastasis Status from Primary Muscle-Invasive Bladder Cancer Histology Slides Using Deep Learning: A Retrospective Multicenter Study. Cancers (Basel). 2023 May 31;15(11):3000. (通讯作者) 7. Xiong Y, Jian J, Yu H, Wu J, Mao H, Feng R, Wang L, Jian Y, Liu X. Cyanidin-3-O-glucoside plays a protective role against renal ischemia/ reperfusion injury via the JAK/STAT pathway. Acta Cir Bras. 2023 May 1;38:e381023. (通讯作者) 8. Liu Y, Jian J, Zhang Y, Wang L, Liu X, Chen Z. Construction of cancer- associated fibroblasts related risk signature based on single-cell RNA-seq and bulk RNA-seq data in bladder urothelial carcinoma. Front Oncol. 2023 Apr 14;13:1170893. (通讯作者) 9. Zheng Q, Guo L, Yang R, Chen Z, Liu X. Identification of essential genes and drug discovery in bladder cancer and inflammatory bowel disease via text mining and bioinformatics analysis. Curr Comput Aided Drug Des. 2023 Mar 30. (通讯作者) 10.Zheng Q, Yang R, Yang S, Ni X, Li Y, Jiang Z, Wang X, Wang L, Chen Z, Liu X.Development and validation of a deep-learning based assistance system for enhancing laparoscopic control level.Int J Med Robot. 2022 Aug 3:e2449. doi: 10.1002/rcs.2449 (通讯作者) 11.Feng R, Xiong Y, Lei Y, Huang Q, Liu H, Zhao X, Chen Z, Chen H,Liu X, Wang L, Weng X.Lysine-specific demethylase 1 aggravated oxidative stress and ferroptosis induced by renal ischemia and reperfusion injury through activation of TLR4/NOX4 pathway in mice. J Cell Mol Med. 2022 Aug;26(15):4254-4267 (通讯作者) 12.Xiong Y, Pang M, Du Y, Yu X, Yuan J, Liu W, Wang L, Liu X. The LINC01929/miR-6875-5p/ADAMTS12 Axis in the ceRNA Network Regulates the Development of dvanced Bladder Cancer. Front Oncol. 2022 May 12;12:856560 (通讯作者) 13.Mao H, Wang L, Xiong Y, Jiang G, Liu X. Fucoxanthin Attenuates Oxidative Damage by Activating the Sirt1/Nrf2/HO-1 Signaling Pathway to Protect the Kidney from Ischemia-Reperfusion Injury. Oxid Med Cell Longev. 2022 Jan 28;2022:7444430 (通讯作者) 14.Wang T, Chen Z, Chen H, Yu X, Wang L, Liu X. Brusatol inhibits the growth of renal cell carcinoma by regulating the PTEN/PI3K/AKT pathway.J Ethnopharmacol. 2022 Apr 24;288:115020 (通讯作者) 15.Zhang BH, Liu H, Yuan Y, Weng XD, Du Y, Chen H, Chen ZY, Wang L, Liu XH. Knockdown of TRIM8 Protects HK-2 Cells Against Hypoxia/Reoxygenation-Induced Injury by Inhibiting Oxidative Stress-Mediated Apoptosis and Pyroptosis via PI3K/Akt Signal Pathway. Drug Des Devel Ther. 2021 Dec 10;15:4973-4983 (通讯作者) 16.Zhang J, Chen H, Weng X, Liu H, Chen Z, Huang Q, Wang L, Liu X. RCAN1.4 attenuates renal fibrosis through inhibiting calcineurin-mediated nuclear translocation of NFAT2.Cell Death Discov. 2021 Oct 27;7(1):317 (通讯作者) 17.Zhao X, Wang D, Wan S, Liu X, Wang W, Wang L. The Suppression of Pin1-Alleviated Oxidative Stress through the p38 MAPK Pathway in Ischemia- and Reperfusion-Induced Acute Kidney Injury. Oxid Med Cell Longev. 2021 Jul 30;2021:1313847(通讯作者) 18.Wang X, Guo J, Wang L, Wang M, Weng X, Chen H, Liu X. Modified completely intrafascial radical cysprostatectomy for bladder cancer: a single-center, blinded, controlled study.BMC Cancer. 2021 Aug 3;21(1):887(通讯作者) 19.Liu H, Wang W, Weng X, Chen H, Chen Z, Du Y, Liu X, Wang L. The H3K9 histone methyltransferase G9a modulates renal ischemia reperfusion injury by targeting Sirt1. Free Radic Biol Med. 2021 Aug 20;172:123-135(通讯作者) 20.Qin XK, Du Y, Liu XH, Wang L. LSD1 Promotes Prostate Cancer Cell Survival by Destabilizing FBXW7 at Post-Translational Level. Front Oncol. 2021 Feb 23;10:616185(通讯作者)